The 2025 American Heart Association (AHA) Scientific Sessions concluded on November 10th. Professor Li Jianping, Vice President of Peking University First Hospital (PKUFH) and Director of the Institute of Cardiovascular Diseases, delivered the opening keynote address as the research team representative. He presented the Phase II clinical trial results of the Chinese original drug DR10624 in patients with severe hypertriglyceridemia to the global audience. This marks the first time a Chinese cardiovascular specialist has taken the podium with original drug research findings, representing a historic breakthrough in China’s cardiovascular metabolic field. Additionally, the one-year follow-up results from Professor Li’s team’s FAIR-PILOT study were presented as a Late-Breaking finding in the “Pan-Vascular Intervention” session, propelling interventional diagnosis and treatment of renal artery stenosis into the era of precision medicine.

The American Heart Association 2025 Scientific Sessions (AHA 2025), as the most influential academic gathering in the global cardiovascular field, brought together top experts and scholars from around the world to present cutting-edge scientific research findings, collectively advancing in-depth exploration and scientific progress in this domain. On this highly anticipated international stage, Professor Li Jianping and his team from China delivered two significant research findings. This presentation once again demonstrated the rising scientific strength and innovative vitality of China to the world, while also highlighting the outstanding contributions made by PKUFH—a core force within China’s national healthcare system—to advancing the “Healthy China” initiative.

Written by: Lang Lang

Edited by: Liu Xin

Source: PKUFH